surpass trial tirzepatide SURMOUNT-1 Trial

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics

28.86

★★★★☆4.8 (126)

💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that tirzepatide was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What

21.95

★★★★★4.9 (98)

Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials

25.23

★★★★★5.0 (157)

Tirzepatide (Mounjaro) received a priority review from @US_FDA for #T2D reflecting the unprecedented reductions in A1c and #weightloss across the SURPASS P3 clinical trial program

22.72

★★★★★4.7 (84)

Tirzepatide Significantly Reduced A1C and Body Weight in People with Type 2 Diabetes in Two Phase 3 Trials from Lilly's SURPASS Program

28.10

★★★★★4.9 (203)

Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme - Bergman - 2025 - Diabetes, Obesity and Metabolism

28.11

★★★★★5.0 (176)

Media Centre

27.51

★★★★★4.8 (132)